Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review

Willem J M Dewilde1, Paul W A Janssen2, Freek W A Verheugt3

  • 1Department of Cardiology, Amphia Hospital, Breda, the Netherlands.

Insights

For patients on chronic oral anticoagulation undergoing stenting, triple therapy with aspirin and clopidogrel increases bleeding risk. Evidence suggests aspirin may not be necessary, challenging current guidelines for preventing thromboembolic events.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic oral anticoagulation is standard for mechanical heart valves and atrial fibrillation (CHA2DS2-VASc score ≥1).
  • Percutaneous coronary intervention with stenting in these patients necessitates dual antiplatelet therapy alongside anticoagulation.
  • Historically, triple therapy (VKA, aspirin, clopidogrel) was recommended, but major bleeding is a significant concern.

Purpose of the Study:

  • To evaluate the necessity of aspirin in triple therapy for patients on oral anticoagulation undergoing stenting.
  • To determine the optimal balance between preventing thromboembolic events and minimizing bleeding risk in this patient population.

Main Methods:

  • Review of recent studies, including a prospective randomized trial, investigating triple therapy regimens.
  • Analysis of evidence regarding the efficacy and safety of adding aspirin to vitamin K antagonists and clopidogrel.

Main Results:

  • The evidence supporting the addition of aspirin to vitamin K antagonists and clopidogrel appears weakened.
  • Major bleeding is a recognized significant risk associated with traditional triple therapy.

Conclusions:

  • Re-evaluation of aspirin's role in triple therapy for anticoagulated patients undergoing stenting is warranted.
  • Finding an optimal antithrombotic strategy to prevent stent thrombosis and stroke without excessive bleeding remains a critical clinical challenge.

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...